RNS Number : 6785Z
Medpal AI PLC
08 April 2026
REACH non-regulatory announcement
8 April 2026
MedPal AI plc
(the "Company" or "MedPal AI")
Updated Research Note
MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, is pleased to announce the release of an updated research note by Optimo Research, alongside a new investor interview with CEO Jason Drummond.
On Thursday 2 April, Optimo Research Ltd updated its coverage of MedPal AI, covering the significant progress made by the company since its IPO in August 2025.
The research can be downloaded on the Optimo Research website here:
https://www.optimocapital.co.uk/library-2
In addition, in a new investor interview CEO Jason Drummond has shared how a combination of AI-driven diagnostics, clinician access, and robotic dispensing has enabled rapid growth, with over 200,000 prescription orders processed since launch. The interview can be accessed on the ADVFN website here:
https://uk.advfn.com/market-news/article/14037/how-medpal-ai-scaled-to-40000-prescriptions-in-months-and-what-comes-next
For further information please visit www.medpalplc.com or contact:
MedPal AI plc Jason Drummond, Chief Executive Officer
Via Square1 Consulting
Clear Capital Markets Limited Bob Roberts
+44 (0) 20 3869 6080
Square1 Consulting David Bick
+44 (0) 20 7929 5599 +44 (0) 7831 381201
About MedPal AI
MedPal AI is a UK-based digital health company building the MedPal Health OS - a vertically integrated, closed-loop platform spanning AI wellness, clinical services, and automated pharmacy fulfilment. Its core app aggregates data from over 100 wearable devices and health apps (including Apple Health, Fitbit, Garmin, and Whoop) into a unified health profile, offering personalised, non-clinical lifestyle guidance through its AI wellness coach and acting as the consumer front door to the Company's clinical and pharmacy services.
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms.
The Company's LEI is 984500EDP8B0A14CBA61.
Follow us on social media:
X: @MedPalPlc
LinkedIn: MedPal AI plc
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only/non-regulatory news releases Into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or any other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAFLFVLSSITIIR
